Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Orlen beats expectations with its best quarter since 2023 📈
US OPEN: Further records on Wall Street at risk
Market wrap: ASML and Infineon support sentiments in Europe
PDD shares plunge over 7% following earnings report⏰